Skip to main content
. 2012 May 16;5:239. doi: 10.1186/1756-0500-5-239

Figure 6.

Figure 6

ERK1/2 activation was assessed in NCI-H1299 and A549 lung cancer cells over-expressing RASSF1C using antibodies that recognize phosphospecific or total ERK1 and ERK2. The level of phosphorylated ERK1/2 in cells over-expressing RASSF1C (NCI-1C and A549-1C significantly higher compared to control cells (NCI-BB and A549-BB).